Aeterna Zentaris (NASDAQ:AEZS) Earns Sell Rating from Analysts at StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of Aeterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) in a report released on Sunday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Aeterna Zentaris Stock Performance

Shares of NASDAQ AEZS opened at $3.80 on Friday. The stock’s 50-day simple moving average is $4.94 and its 200-day simple moving average is $6.55. The firm has a market capitalization of $6.81 million, a PE ratio of -0.26 and a beta of 1.55. Aeterna Zentaris has a fifty-two week low of $3.96 and a fifty-two week high of $12.00.

Aeterna Zentaris Company Profile

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis.